Resolution of Polycystic Ovaries by Unani Formulation: A Case Report
Abstract
Poly-cystic Ovarian Syndrome (PCOS) is a heterogeneous multisystem endocrinopathy in women, characterized by hyperandrogenism, chronic an-ovulation and poly-cystic ovaries. It may set in early adolescent life but clinically manifest in the reproductive age with long term implications of diabetes, hypertension, hyperlipidemia and cardiovascular disease. Exact pathophysiology is not clearly understood. Clinical features of PCOS develop with oligomenorrhoea (87%) or short period of amenorrhoea (26%) followed by prolonged or heavy periods. Data has indicated that in patients of PCOS, obesity occurs in more than 50% while as infertility has been reported in 20%. In classical Unani literature this disease has not been mentioned under the term of PCOS but its clinical features have been mentioned under the heading of ehtebas-e-tams (amenorrhoea), uqr (infertility), saman-e-mufrat (obesity) and hirsutism, which are nearly same as per recent reports on PCOS. This disease can be treated by those drugs having mudirr-e-haiz (emmenagogue), muqawwi-e-bah (aphrodisiac), muqawwi-e-rahem (uterine tonic), muqawiyat (general tonic) and munzij wa mukhrij-e-balgham (concoctive and phlegm expulsive) properties. Unani system of medicine claims to possess a number of effective and safe drugs that can be used successfully to resolve the cyst and prevent surgical intervention. In the present study a 16 years old, unmarried female, diagnosed with Poly-cystic Ovarian Syndrome on the basis of clinical parameters, laboratory investigation and Ultrasonographic findings. She was treated with Unani formulations i.e. Majoon Dabidul Ward (6 gm), Arq Mako (60 ml) and Arq Kasni (60 ml), twice a day by oral route before meal for three months. After the treatment patient showed significant symptomatic improvement and cysts were completely resolved in USG findings.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.